INTERPENETRATING POLYMER NETWORKS FOR USE IN SUTURABLE AND FLEXIBLE MATERIALS
20240150580 ยท 2024-05-09
Assignee
Inventors
- Aman Kaur (Manchester, NH, US)
- Lina Trigg (Mason, OH, US)
- Barbara Nsiah (Manchester, NH, US)
- Luis ALVAREZ (Lexington, MA, US)
Cpc classification
C12N5/0688
CHEMISTRY; METALLURGY
B33Y10/00
PERFORMING OPERATIONS; TRANSPORTING
C08G2270/00
CHEMISTRY; METALLURGY
C08L39/06
CHEMISTRY; METALLURGY
B33Y70/00
PERFORMING OPERATIONS; TRANSPORTING
A61L27/16
HUMAN NECESSITIES
C09D4/06
CHEMISTRY; METALLURGY
C08L39/06
CHEMISTRY; METALLURGY
A61L27/18
HUMAN NECESSITIES
A61L27/18
HUMAN NECESSITIES
A61L27/3813
HUMAN NECESSITIES
B33Y80/00
PERFORMING OPERATIONS; TRANSPORTING
A61L27/16
HUMAN NECESSITIES
C08L29/04
CHEMISTRY; METALLURGY
A61L2430/00
HUMAN NECESSITIES
C08L29/04
CHEMISTRY; METALLURGY
International classification
C09D4/06
CHEMISTRY; METALLURGY
Abstract
An advanced manufactured interpenetrating polymer network (AM-IPN) comprising: a primary polymer network; a secondary polymer network, wherein the secondary polymer network is bonded to the primary polymer network via one or more crosslinks, wherein one or more of the primary polymer network, the secondary polymer network and the one or more crosslinks are printed using a synthetic bioink is disclosed. Methods of making and using are also disclosed.
Claims
1. An advanced manufactured interpenetrating polymer network (AM-IPN) comprising: a primary polymer network; a secondary polymer network, wherein the secondary polymer network is bonded to the primary polymer network via one or more crosslinks, wherein one or more of the primary polymer network, the secondary polymer network and the one or more crosslinks are printed using a synthetic bioink.
2. The AM-IPN of claim 1, wherein the synthetic bioink comprises one or more of: HPA, in an amount from about 0.5% to about 20%; PEGDA 6000, in an amount from about 0.5% to about 20%; TMPTA 912, in an amount from about 0.05% to about 3%; NAP, in an amount from about 0.05% to about 3%; UV386A, in an amount from about 0.0001% to about 0.5%; Polymer, in an amount from about 0.001% to about 2.0%; and Water, in an amount as a balance.
3. The AM-IPN of claim 2, wherein the polymer comprises one or more of: polyethylene oxide (PEO), polyethylenimine (PEI), polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), and combinations thereof.
4. The AM-IPN of claim 3, wherein the polymer is PEO having a molecular weight from about 100000 to about 4000000.
5. The AM-IPN of claim 3, wherein the polymer is PEO in an amount from about 0.005% to about 1%.
6. The AM-IPN of claim 3, wherein the polymer is PEI having a molecular weight from about 25000 to about 75000.
7. The AM-IPN of claim 3, wherein the polymer is PEI in an amount from about 0.005% to about 1%.
8. The AM-IPN of claim 3, wherein the polymer is PVP having a molecular weight from about 1000000 to about 1300000.
9. The AM-IPN of claim 3, wherein the polymer is PVP or PVA in an amount from about 0.005% to about 2%.
10. The AM-IPN of claim 3, wherein the polymer is PVA having a molecular weight from about 89000 to about 98000.
11. (canceled)
12. The interpenetrating network of claim 1, wherein the synthetic bioink comprises one or more of: HPA, in an amount from about 0.5% to about 20%; PEGDA 6000, in an amount from about 0.5% to about 20%; PEGDA 3400, in an amount from about 0.2% to about 15%; NAP, in an amount from about 0.05% to about 3%; UV386A, in an amount from about 0.0001% to about 0.5%; Polymer, in an amount from about 0.001% to about 2.0%; and Water, in an amount as a balance.
13. The AM-IPN of claim 12, wherein the polymer comprises one or more of: polyethylene oxide (PEO), polyethylenimine (PEI), polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), and combinations thereof.
14. The AM-IPN of claim 13, wherein the polymer is PEO having a molecular weight from about 100000 to about 4000000.
15. The AM-IPN of claim 13, wherein the polymer is PEO in an amount from about 0.005% to about 1%.
16. The AM-IPN of claim 13, wherein the polymer is PEI having a molecular weight from about 25000 to about 75000.
17. The AM-IPN of claim 13, wherein the polymer is PEI in an amount from about 0.005% to about 1%.
18. The AM-IPN of claim 13, wherein the polymer is PVP having a molecular weight from about 1000000 to about 1300000.
19. The AM-IPN of claim 13, wherein the polymer is PVP or PVA in an amount from about 0.005% to about 2%.
20. The AM-IPN of claim 13, wherein the polymer is PVA having a molecular weight from about 89000 to about 98000.
21. (canceled)
22. A method of making an advanced manufactured interpenetrating polymer network (AM-IPN) comprising: printing one or more of a primary polymer network, a secondary polymer network and one or more crosslinks using a synthetic bioink and a 3D printing technique; and assembling and/or printing the AM-IPN to form an assembled AM-IPN.
23-30. (canceled)
31. A method of using an advanced manufactured interpenetrating polymer network (AM-IPN) comprising: modifying a surface of the AM-IPN to attach small airway epithelial cells (SAEC) to form a modified AM-IPN.
32. (canceled)
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0038] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the U.S. Patent and Trademark Office upon request and payment of a required fee.
[0039] The details of one or more implementations of the subject matter described in this specification are set forth in the accompanying drawings and the description below. Other features, aspects, and advantages of the subject matter will become apparent from the description, the drawings, and the claims.
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
[0111]
[0112]
[0113]
[0114]
DETAILED DESCRIPTION
[0115] The following detailed description of various embodiments of the present invention references the accompanying drawings, which illustrate specific embodiments in which the invention can be practiced. While the illustrative embodiments of the invention have been described with particularity, it will be understood that various other modifications will be apparent to and can be readily made by those skilled in the art without departing from the spirit and scope of the invention. Accordingly, it is not intended that the scope of the claims appended hereto be limited to the examples and descriptions set forth herein but rather that the claims be construed as encompassing all the features of patentable novelty which reside in the present invention, including all features which would be treated as equivalents thereof by those skilled in the art to which the invention pertains. Therefore, the scope of the present invention is defined only by the appended claims, along with the full scope of equivalents to which such claims are entitled.
Advanced Manufactured Interpenetrating Polymer Network (AM-IPN)
[0116] An interpenetrating polymer network is a primary network bonded to a secondary network via non-covalent bonds.
[0117]
[0118]
[0119]
[0120] Any suitable synthetic bioink may be used. For example, suitable synthetic bioinks, include, but are not limited to, AA42, AI15, AI28, and AJ55 Bioinks, as described herein.
[0121] Exemplary Bioinks
TABLE-US-00001 AA42 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 3400 7.6-8.4 LAP 0.95-1.05 UV386A 0.114-0.126 Water 76.84-84.92 Total 100
TABLE-US-00002 AI15 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 130.4 HPA 9.5-10.5 97699847GO 10Nov20 PEGDA 6052 PEGDA 6000 - 4.75-5.25 6000 BB0308-78 TMPTA 956 SR9035 - 0.95-1.05 912 LDJ1138 NAP 311.26 NAP -- 1.43-1.58 0010769 UV386A 478.03 UV386A - 0.152-0.168 0917-20A- 386A Water 28.5-31.5 Total 100
TABLE-US-00003 AI28 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 4.75-5.25 TMPTA 912 2.85-3.15 NAP 1.52-1.68 UV386A 0.152-0.168 Water 76.23-84.25 Total 100
TABLE-US-00004 AJ55 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 4.75-5.25 TMPTA 912 1.9-2.1 NAP 0.95-1.05 UV386A 0.171-0.189 Water 76.78-84.86 Total 100
[0122] Any suitable polymer may be incorporated into a synthetic bioink. For example, suitable polymers include, but are not limited to, polyethylene oxide (PEG), Polyethylenimine (PEI), Polyvinylpyrrolidone (PVP), and Polyvinyl Alcohol (PVA).
[0123] Exemplary Polymers
TABLE-US-00005 Polyethylene Polyvinyl Oxide Polyethylenimine Polyvinylpyrrolidone Alcohol (PEO) (PEI) (PVP) (PVA) Molecular 4000000, 750000 1300000 93500 Weight 1000000, 25000 1000000 (MW) 100000 Solubility 0.5% stock solution 50% stock solution 2% stock solution 2% in stock solution Heat at 100? C., No heat, mix at No heat, mix at Heat at 200? C., mix at 600 RPM 600 RPM 200 RPM mix at 600 RPM Compatibility Not compatible with PEGDA 700 and Triacetate
[0124] Exemplary Bioink Ink Formulations and Print Settings for FS20 DLP 3D System Printer
[0125] Polyethylene Oxide (PEO)
[0126] In these examples, a Polyethylene Oxide (PEG) polymer was incorporated into AA42 Bioink (Stock), as follows.
[0127] Polyethylene Oxide 4000000 (0.5% PEG Stock Solution)
[0128] Polyethylene Oxide 4000000 polymer was added to water, heated at 100? C., and mixed at 600 RPM before incorporating the bioink.
[0129] Polyethylene Oxide 1000000 (0.5% PEO Stock Solution)
[0130] Polyethylene Oxide 1000000 polymer was added to water, heated at 100? C., and mixed at 600 RPM before incorporating into bioink.
TABLE-US-00006 AA42 Bioink (Stock) Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 3400 7.6-8.4 LAP 0.95-1.05 UV386A 0.114-0.126 Water 17.04-18.84 Total 35.21-38.91
[0131] In the AA42 Bioink (Stock) solution, the water concentration was reduced slightly (as compared to the AA42 Bioink) so that Polyethylene Oxide polymer stock solutions could be added to prepare the AL35, AL36, AL37, AL38 and AL39 Bioinks.
TABLE-US-00007 AL35 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PEO 4000000 PEO 4000000 - 0.48-0.53 4000000 MKCL3736 Water 59.32-65.56 AA42 35.21-38.91 (Stock) Total 100
TABLE-US-00008 AL36 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PEO 4000000 PEO 4000000 - 0.095-0.105 4000000 MKCL3736 Water 59.70-65.98 AA42 35.21-38.91 (Stock) Total 100
TABLE-US-00009 AL37 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PEO 4000000 PEO 4000000 - 0.048-0.053 4000000 MKCL3736 Water 59.75-66.03 AA42 35.21-38.91 (Stock) Total 100
TABLE-US-00010 AL38 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PEO 1000000 PEO 1000000 - 0.095-0.105 1000000 MKCM8338 Water 59.75-66.03 AA42 35.21-38.91 (Stock) Total 100
TABLE-US-00011 AL39 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PEO 1000000 PEO 4000000 - 0.048-0.053 1000000 MKCM8338 Water 59.75-66.03 AA42 35.21-38.91 (Stock) Total 100
TABLE-US-00012 AL42 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 4.75-5.25 TAC 2.85-3.15 NAP 1.52-1.68 UV386A 0.152-0.168 Water 75.75-83.73 PEI 25000 25000 0.475-0.525 Total 100
TABLE-US-00013 AL43 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 4.75-5.25 TAC 0.95-1.05 NAP 1.52-1.68 UV386A 0.152-0.168 Water 75.75-83.73 PEO 40000000 4000000 0.048-0.053 Total 100
TABLE-US-00014 AL44 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 4.75-5.25 TAC 1.9-2.1 NAP 1.52-1.68 UV386A 0.152-0.168 Water 75.75-83.73 PEO 40000000 4000000 0.048-0.053 Total 100
TABLE-US-00015 AL45 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 4.75-5.25 TAC 2.85-3.15 NAP 1.52-1.68 UV386A 0.152-0.168 Water 75.75-83.73 PEO 40000000 4000000 0.048-0.053 Total 100
TABLE-US-00016 AL47 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 4.75-5.25 PEGDA 700 2.85-3.15 PEGDA 6000 4.75-5.25 NAP 1.43-1.58 UV386A 0.152-0.168 Water 81.07-89.61 Total 100
TABLE-US-00017 AL48 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 4.75-5.25 TAC 3.8-4.2 NAP 1.52-1.68 UV386A 0.152-0.168 Water 75.75-83.73 PEO 40000000 4000000 0.048-0.053 Total 100
[0132] Rheology Testing
[0133]
[0134]
[0135]
[0136]
[0137] Under the inertia settings, a new calibration reading was accepted because the reading was acceptable (e.g., close to previous calibration reading).
[0138] Under the oscillatory setting, a new mapping was calibrated.
[0139] The light source was calibrated with a black cover of a UV radiometer placed on the surface of the light source where a sample may be placed.
[0140]
[0141]
[0142] Under the inertia setting, a new calibration reading was accepted because the reading was acceptable (e.g., close to the previous reading)
[0143] Under the friction setting, a new calibration reading was accepted because the reading was acceptable (e.g., close to the previous reading).
[0144] The rheometer was lowered so that it was slightly above the sample placement and select a zero gap icon.
[0145] The rheometer was raised to a loading gap.
[0146] Under the Geometries tab, the gap was set to 200 ?m and the minimum sample volume was set to 0.062 mL.
[0147]
[0148]
[0149]
[0150] 75 ?L of sample was loaded onto the middle of the rheometry plate. Any bubble were removed by gently poking the bubbles with a needle. The gap was set to 200 ?m. The black UV cover was lowered before each experiment to shield from UV light.
[0151]
TABLE-US-00018 AL35, AL36, AL37 and AL38 Bioinks Rheology Data Bioink Onset Time (s) Storage Modulus at 50 s AL35 20 4.42 AL36 18.5 14.52 AL37 17.5 16.73 AL38 19 13.18
TABLE-US-00019 AL35, AL36, AL37 and AL38 Bioinks Print Settings for FS20 DLP 3D System Printer Region Baselayer B Units Layer E Units Power 50 mW/cm.sup.2 Power 50 mW/cm.sup.2 Exposure 1000 ms Exposure 600 ms Time Time Pump 300 ?m Pump 300 ?m Distance Distance Uptime 1000 ms Uptime 1500 ms Uptime 1000 ms Uptime 1500 ms Pause Pause Downtime 1000 ms Downtime 1500 ms Downtime 1000 ms Down time 2000 ms Pause Pause
[0152] Compression Testing
[0153] Dynamic Mechanical Analysis (DMA) is a technique that is frequently used to characterize a material's properties as a function of atmosphere, frequency, stress, temperature, time, and combinations thereof.
[0154] The compression testing is performed using a DMA 850 instrument designed to measure viscoelastic properties (e.g., modulus, damping) of rigid and soft solid materials. The compression testing may be used to measure the properties of low to medium modulus materials, including gels and weak elastomers. The sample must support a static (preload) force during compression testing. The sample should have as high of a thickness-to-diameter ratio as possible, depending on the sample preparation and instrument limits.
[0155] Typical samples are printed discs (e.g., about 8 mm in diameter, about 3 mm thickness).
[0156] A printed disc is mounted in a clamp, one part of which is stationary and the other part is connected to a drive motor, and is movable. The motor directly applies a deformation to the printed disc.
[0157] The compression modulus is calculated from the slope of the stress (kPa) to the strain (%) in a linear region, which is typically from 0% to 10% of the initial strain. To ensure that the slope is calculated over the linear region, an R.sup.2 value of the modulus should be between about 0.95 to about 0.99.
[0158] Compression failure strength and strain are the values of maximum stress (kPa) and maximum strain (%) at which the printed disc fails.
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165]
[0166] The printed discs should be stored in 1?DPBS overnight before the compression testing. Immediately before placing the printed discs in the clamps excess 1?DPBS should be gently blotted away using a Kimwipe.
[0167]
[0168] The printed disc is placed between the bottom and top clamps, making sure that the printed disc is placed in the center between the clamps. The movable top clamp is brought down to slightly touch the printed disc.
[0169] Under a Procedure tab, the desired compression parameters (e.g., final strain percentage, strain rate) should be entered. Typical compression tests are performed at about 20% strain/minute.
[0170]
[0171] After the compression testing is stopped, Young's modulus may be calculated from the stress-strain curve slop in the linear region (e.g., about 0% to about 10% strain). The ultimate compressive strain (%) and strength (kPa) may be calculated at the failure point. An average of about six printed discs should be calculated for Young's modulus and failure strain.
[0172]
[0173]
[0174]
[0175]
[0176]
[0177]
[0178]
TABLE-US-00020 AL35 Bioink Compression Data Area Under Curve % Maximum Strain 2945.1 188.91 2751.15 170.74 3228.81 199.01 2152.97 134.12 2769.71 173.20
TABLE-US-00021 AL36 Bioink Compression Data Area Under Curve % Maximum Strain 4910.25 308.44 2481.46 145.35 2655.55 150.95 3010.47 193.83 3078.87 181.54 2834.68 165.00 3161.88 190.85
[0179]
[0180]
[0181]
[0182]
TABLE-US-00022 AL49 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 6000 4.75-5.25 TAC 2.85-3.15 PEO 4000000 4000000 0.095-0.105 NAP 1.52-1.68 UV386A 0.152-0.168 Water 76.09-84.09 Total 100
[0183] The hydrogel material is placed in a bioreactor; and the tubes for the vasculature and airway are inserted from a blue cap of the bioreactor. This tests the ability of the hydrogel material to expand around the tube.
[0184]
[0185] Biocompatibility Testing
[0186] Printed discs (e.g., hydrogels) of AL36 Bioink were printed (e.g., about 8 cm diameter, about 3 mm thickness).
[0187] Small airway epithelial cells were seeded on the printed discs (e.g., hydrogels). This was done in clear bottom cell culture plates.
[0188] At each time point, the printed disks e.g., hydrogels) were placed under a microscope to determine whether small airway epithelial cell attachment was still occurring and whether the small airway epithelial cells remained unstained.
[0189]
[0190]
[0191]
[0192] Suture Testing
[0193] Using a 45 mm gauge needle, the needle was passed through a solid part of an advanced manufactured hydrogel material (capsulent). The hydrogel material (capsulent) was inspected for any cracking. The purpose of this test was to see if the hydrogel material could be sutured without cracking or falling apart.
[0194]
[0195]
[0196] The AL35 Bioink swelled and disintegrated during surface modification. However, the AL36 Bioink remained intact during surface modification but showed decreased attachment of small airway epithelial cells (SAEC) by Day 4.
[0197] The AA42 Bioink forms a high crosslinking density of the interpenetrating polymer network in the Bioink. As such, the Polyethylene Oxide (PEO) polymer may be tightly bonded in the interpenetrating polymer network.
[0198] Polyethylenimine (PEI)
[0199] In these examples, a Polyethylenimine (PEI) polymer was incorporated into AI28 Bioink (Stock), as follows.
[0200] Polyethylenimine (PEI) 750000 (50% PEI Stock Solution)
[0201] Polyethylenimine (PEI) 750000 was dissolved in water, and mixed at 600 RPM before adding other components.
[0202] Polyethylenimine (PEI) 25000 (50% PEI Stock Solution)
[0203] Polyethylenimine (PEI) 25000 was dissolved in water, and mixed at 600 RPM before adding other components
TABLE-US-00023 AI28 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 4.75-5.25 TMPTA 912 2.85-3.15 NAP 1.52-1.68 UV386A 0.152-0.168 Water 76.23-84.25 Total 100
TABLE-US-00024 AL60 Bioink (Stock) Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 130.14 HPA -- 9.5-10.5 769984760 PEGDA 6052 PEGDA 6000 - 4.75-5.25 6000 BB0308-178 PEGDA 6000 - BB0308-180 PEGDA 6000 - BB0308-181 PEGDA 3452 PEGDA 3400 - 2.85-3.15 3400 BB0308-73 PEGDA 3400 - BB0308-73 PEGDA 3400 - BB0308-90 NAP 311.26 NAP -- 1.43-1.58 0010769 UV386A 478.03 UV386A 903- 0.114-0.126 20A-386A Water 28.5-31.5 Total 50
TABLE-US-00025 AL60 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) Water 47.86-52.90 AL60 (Stock) 47.14-52.10 Total 100
TABLE-US-00026 AL61 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PEI 750000 750000 PEI 750000 - 0.048-0.053 BCC0334 Water 47.81-52.85 AL60 47.14-52.10 (Stock) Total 100
TABLE-US-00027 AL62 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PEI 750000 750000 PEI 750000 - 0.095-0.105 BCC0334 Water 47.77-52.79 AL60 47.14-52.10 (Stock) Total 100
TABLE-US-00028 AL63 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PEI 750000 750000 PEI 750000 - 0.475-0.525 BCC0334 Water 47.39-52.37 AL60 47.14-52.10 (Stock) Total 100
TABLE-US-00029 AL64 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PEI 25000 25000 PEI 25000 - 0.095-0.105 408727 Water 47.77-52.79 AL60 47.14-52.10 (Stock) Total 100
TABLE-US-00030 AL65 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PEI 25000 25000 PEI 25000 - 0.048-0.053 408727 Water 47.81-52.85 AL60 47.14-52.10 (Stock) Total 100
TABLE-US-00031 AL66 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PEI 25000 25000 PEI 25000 - 0.475-0.525 408727 Water 47.39-52.37 AL60 47.17-52.10 (Stock) Total 100
[0204] Rheology Testing
[0205] The rheology testing discussed above and shown in
[0206]
TABLE-US-00032 AL60, AL62, AL64, AL65 and AL66 Bio ink Rheology Data Bioink Onset Time Storage Modulus at 50 s AL60 2.5 12.81 AL62 2.5 12.39 AL64 2.5 20.21 AL65 2.5 16.79 AL66 2.5 18.92
TABLE-US-00033 AL60 Bioink Print Settings for FS20 DLP 3D System Printer Region Baselayer B Units Layer E Units Power 50 mW/cm.sup.2 Power 50 mW/cm.sup.2 Exposure 1500 ms Exposure 1200 ms Time Time Pump 300 ?m Pump 300 ?m Distance Distance Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Pause Pause Downtime 1000 ms Downtime 1500 ms Downtime 2000 ms Down time 2000 ms Pause Pause
TABLE-US-00034 AL61 Bioink Print Settings for FS20 DLP 3D System Printer Region Baselayer B Units Layer E Units Power 50 mW/cm.sup.2 Power 50 mW/cm.sup.2 Exposure 1000 ms Exposure 800 ms Time Time Pump 300 ?m Pump 300 ?m Distance Distance Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Pause Pause Downtime 1000 ms Downtime 1500 ms Downtime 2000 ms Down time 2000 ms Pause Pause
TABLE-US-00035 AL62 (50 mW/cm.sup.2) Bioink Print Settings for FS20 DLP 3D System Printer Region Baselayer B Units Layer E Units Power 50 mW/cm.sup.2 Power 50 mW/cm.sup.2 Exposure 100 ms Exposure 7500 ms Time Time Pump 300 ?m Pump 300 ?m Distance Distance Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Pause Pause Downtime 1000 ms Downtime 1500 ms Downtime 2000 ms Down time 2000 ms Pause Pause
TABLE-US-00036 AL62 (150 mW/cm.sup.2) Bioink Print Settings for FS20 DLP 3D System Printer Region Baselayer B Units Layer E Units Power 150 mW/cm.sup.2 Power 150 mW/cm.sup.2 Exposure 1000 ms Exposure 500 ms Time Time Pump 300 ?m Pump 300 ?m Distance Distance Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Pause Pause Downtime 1000 ms Downtime 1500 ms Downtime 2000 ms Down time 2000 ms Pause Pause
TABLE-US-00037 AL62 (200 mW/cm.sup.2) Bioink Print Settings for FS20 DLP 3D System Printer Region Baselayer B Units Layer E Units Power 200 mW/cm.sup.2 Power 200 mW/cm.sup.2 Exposure 1000 ms Exposure 500 ms Time Time Pump 300 ?m Pump 300 ?m Distance Distance Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Pause Pause Downtime 1000 ms Downtime 1500 ms Downtime 2000 ms Down time 2000 ms Pause Pause
[0207] Swelling Testing
[0208] Printed discs (e.g., hydrogels) of AL36 Bioink were printed (e.g., about 8 cm diameter, about 3 mm thickness).
[0209] The printed discs were weighed before soaking (i.e., initial weight). Immediately before weighing, any excess resin should be gently blotted from the printed disc using a Kimwipe.
[0210] The printed discs were placed in a 24-well plate. 1?DPBS++ was added to each well to about 5? the volume of the printed discs (i.e., a 8 mm?3 mm printed disc has a volume of about 150 ?L, thus, about 1 mL of 1?DPBS++ should be added to each well).
[0211] The printed discs should be weighed after soaking in 1?DPBS++ for 24-hours at 37? C. (i.e., final weight after 24-hours). Immediately before weighing, any excess 1?DPBS++ should be gently blotted from the printed disc using a Kimwipe.
[0212] The % swelling may be calculated, as follows:
[0213] Fresh 1?DPBS++ was added to each well. To continue the swelling testing, the printed discs should be weighed again after soaking in 1?DPBS++ for up to 4 or 7 days at 37? C. (i.e., final weight after 4 or 7 days).
TABLE-US-00038 AL62 Bioink Swelling Data at 37? C. Initial Weight 24 Hours Final Weight After 7 Days (g) (g) (g) 0.178 0.211 0.205 0.171 0.198 0.192 0.172 0.193 0.194 0.178 0.199 0.205 0.182 0.203 0.198 0.174 0.197 0.195 0.188 0.209 0.210 0.183 0.200 0.173
[0214] Compression Testing
[0215] The compression testing is discussed above and shown in
[0216]
[0217]
[0218]
[0219]
[0220]
[0221]
TABLE-US-00039 AL60 Bioink Compression Data Area Under Curve % Maximum Strain 3796.09 286.60 4427.06 261.01 4435.10 286.20 2818.34 172.02 3811.92 132.85 4159.17 161.70 3907.94 216.73
TABLE-US-00040 AL62 (50 mW/cm.sup.2, 2750 ms) Bioink Compression Data Area Under Curve % Maximum Strain 3224.50 183.94 1888.31 94.14 1902.74 85.04 2686.84 153.69 4899.90 256.91 2834.02 154.58 2906.05 154.72
TABLE-US-00041 AL62 (150 mW/cm.sup.2, 500 ms) Bioink Compression Data Area Under Curve % Maximum Strain 3830.12 211.54 4232.07 233.76 5645.61 265.12 3123.30 172.02 3811.92 218.95 4959.65 263.49 4267.11 227.48
TABLE-US-00042 AL62 (200 mW/cm.sup.2, 2500 ms) Bioink Compression Data Area Under Curve % Maximum Strain 2133.17 108.33 2544.82 134.07 2586.95 152.72 1834.83 101.74 2962.35 167.12 2302.73 109.05 2394.14 128.84
[0222] The AL62 Bioink, when printed at 50 mW/cm.sup.2, resulted in a softer hydrogel than the AL60 Bioink (Stock); and the AL62 Bioink, when printed at 150 mW/cm.sup.2, resulted in a tougher hydrogel than the AL60 Bioink (Stock).
[0223] The Polyethylenimine (PEI) polymer was incorporated into AL60 Bioink (Stock) when printed at 150 mW/cm.sup.2 and 200 mW/cm.sup.2.
[0224] Suture Testing
[0225] Using a 45 mm gauge needle, the needle was passed through a solid part of an advanced manufactured hydrogel material (capsulent). The hydrogel material (capsulent) was inspected for any cracking. The purpose of this test was to see if the hydrogel material could be sutured without cracking or falling apart.
[0226]
[0227]
[0228]
[0229] The AL62 Bioink, when printed at 50 mW/cm.sup.2 and 100 mW/cm.sup.2, failed the suture test. However, the AL62 Bioink, when printed at 150 mW/cm.sup.2 and 200 mW/cm.sup.2 passed the suture test.
[0230] Polyvinylpyrrolidone (PVP)
[0231] In these examples, a Polyvinylpyrrolidone (PVP) polymer was incorporated into AI28 and AJ55 Bioinks, as follows.
[0232] The PVP polymer has a bulky side chain so the polymer could potentially cause stiffness in AI28 Bioink.
TABLE-US-00043 Polyvinylpyrrolidone (PVP) 130000 Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVP 130000 PVP 130000 - 0.95-1.05 130000 MKCP1726 Water 98.95-99.05 Total 100
TABLE-US-00044 AI28 Bioink (Stock) Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 4.75-5.25 TMPTA 912 2.85-3.15 NAP 1.52-1.68 UV386A 0.152-0.168 Water 76.23-84.25 Total 100
TABLE-US-00045 AL67 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVP 130000 PVP 130000 - 0.95-1.05 130000 MKCP1726 Water 46.78-51.70 AI28 47.27-52.25 (Stock) Total 100
TABLE-US-00046 AL68 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVP 130000 PVP 130000 - 0.475-0.525 130000 MKCP1726 Water 47.25-52.23 AI28 47.27-52.25 (Stock) Total 100
TABLE-US-00047 AL69 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVP 130000 PVP 130000 - 0.095-0.105 130000 MKCP1726 Water 47.63-52.65 AI28 47.27-52.25 (Stock) Total 100
TABLE-US-00048 AL70 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVP 130000 PVP 130000 - 0.048-0.053 130000 MKCP1726 Water 47.68-52.70 AI28 47.27-52.25 (Stock) Total 100
TABLE-US-00049 AI19 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 4.75-5.25 PEGDA 6000 4.75-5.25 PEGDA 575 2.85-3.15 NAP 1.9-2.1 UV386A 0.133-0.147 Water 80.62-89.10 Total 100
TABLE-US-00050 AL59 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 4.75-5.25 PEGDA 4.75-5.25 6000 NAP 1.52-1.68 UV386A 0.114-0.126 Water 75.75-83.73 Total 100
TABLE-US-00051 AL71 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVP 130000 PVP 130000 - 0.95-1.05 130000 MKCP1726 Water 49.76-55.0 AI19 44.29-48.95 (Stock) Total 100
TABLE-US-00052 AI15 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 130.4 HPA 9.5-10.5 97699847GO 10Nov20 PEGDA 6052 PEGDA 6000 - 4.75-5.25 6000 BB0308-78 TMPTA 956 SR9035 - 0.95-1.05 912 LDJ1138 NAP 311.26 NAP -- 1.43-1.58 0010769 UV386A 478.03 UV386A - 0.152-0.168 0917-20A- 386A Water 76.32-84.36 Total 100
TABLE-US-00053 AJ55 Bioink (Stock) Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 4.75-5.25 TMPTA 912 1.9-2.1 NAP 0.95-1.05 UV386A 0.171-0.189 Water 76.78-84.86 Total 100
TABLE-US-00054 AI15 Bioink (Stock) Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 130.4 HPA 9.5-10.5 97699847GO 10Nov20 PEGDA 6052 PEGDA 6000 - 4.75-5.25 6000 BB0308-78 TMPTA 956 SR9035 - 0.95-1.05 912 LDJ1138 NAP 311.26 NAP -- 1.425-1.575 0010769 UV386A 478.03 UV386A - 0.152-0.168 0917-20A- 386A Water 28.5-31.5 Total 100
TABLE-US-00055 AL72 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVP 130000 PVP 130000 - 0.95-1.05 130000 MKCP1726 Water 47.82-52.86 AI15 45.28-50.04 (Stock) Total 100
TABLE-US-00056 AL73 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVP 130000 PVP 130000 - 0.475-0.525 130000 MKCP1726 PEGTA 956 SR9035 - 0.95-1.05 912 LDJ1138 Water 48.30-53.38 AI15 45.28-50.04 (Stock) Total 100
TABLE-US-00057 AL74 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVP 130000 PVP 130000 - 0.095-0.105 130000 MKCP1726 PEGTA 956 SR9035 - 0.95-1.05 912 LDJ1138 Water 48.68-53.80 AI15 45.28-50.04 (Stock) Total 100
TABLE-US-00058 AL75 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVP 130000 PVP 130000 - 0.048-0.053 130000 MKCP1726 PEGTA 956 SR9035 - 0.95-1.05 912 LDJ1138 Water 48.73-53.85 AI15 45.28-50.04 (Stock) Total 100
[0233] Rheology Testing
[0234] The rheology testing is discussed above and shown in
[0235]
TABLE-US-00059 Rheology Data Bioink Onset Time Storage Modulus at 50 s AL68 3 16.77 AL69 3.5 17.97 AL70 2 18.71 AL72 3 17.39 AL73 3 20.67
TABLE-US-00060 AL68, AL70, AL72, AL73 and AL74 Bioinks Print Settings for FS20 DLP 3D System Printer Region Baselayer B Units Layer E Units Power 50 mW/cm.sup.2 Power 50 mW/cm.sup.2 Exposure 2000 ms Exposure 1700 ms Time Time Pump 300 ?m Pump 300 ?m Distance Distance Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Pause Pause Downtime 1000 ms Downtime 1500 ms Downtime 2000 ms Down time 2000 ms Pause Pause
[0236] Compression Testing
[0237] The compression testing is discussed above and shown in
[0238]
[0239]
[0240]
[0241]
[0242]
[0243]
TABLE-US-00061 AL68 Bioink Compression Data Area Under Curve % Maximum Strain 3204.69 199.05 4373.49 251.27 3337.19 184.19 2879.96 181.19 4374.83 260.40 4347.76 263.93 3752.98 223.47
TABLE-US-00062 AL70 Bioink Compression Data Area Under Curve % Maximum Strain 2912.44 174.48 2270.52 124.39 4008.33 245.69 4311.78 253.34 3805.09 232.96 3389.07 196.91 3449.54 204.63
TABLE-US-00063 AL72 Bioink Compression Data Area Under Curve % Maximum Strain 3423.97 209.84 3032.70 155.24 3281.38 207.95 3695.25 183.57 3231.84 188.50 3150.41 176.93 3302.59 187.01
TABLE-US-00064 AL73 Bioink Compression Data Area Under Curve % Maximum Strain 4027.78 255.23 3852.70 234.92 4421.14 207.95 3695.25 239.71 4094.71 236.51 3533.24 212.05 3937.47 231.061
TABLE-US-00065 AL74 Bioink Compression Data Area Under Curve % Maximum Strain 2042.94 126.11 3359.99 196.88 2062.54 122.42 1988.54 103.10 2957.11 181.29 1657.71 86.71 2344.81 136.09
[0244] The Polyvinylpyrrolidone (PVP) polymer was incorporated into AI28 Bioink (Stock) and AJ55 Bioink (Stock).
[0245] The AL73 Bioink had the best toughness and highest maximum strain while maintaining flexibility.
[0246] Suture Testing
[0247] Using a 45 mm gauge needle, the needle was passed through a solid part of an advanced manufactured hydrogel material (capsulent). The hydrogel material (capsulent) was inspected for any cracking. The purpose of this test was to see if the hydrogel material could be sutured without cracking or falling apart.
[0248]
[0249]
[0250]
[0251] The AL70 Bioink failed the suture test. However, the AL68 and AL73 Bioinks passed the suture test.
[0252] Polyvinyl Alcohol (PVA)
[0253] In these examples, Polyvinyl Alcohol (PVA) polymer was incorporated into AI28 Bioink (Stock), as follows.
[0254] Polyvinyl Alcohol (PVA) (2% PVP Stock Solution)
[0255] Polyvinyl alcohol (PVA) was added to water, heated at 200? C., and mixed at 200 RPM before incorporating into the bioink.
TABLE-US-00066 AI28 Bioink (Stock) Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 9.5-10.5 PEGDA 6000 4.75-5.25 TMPTA 912 2.85-3.15 NAP 1.52-1.68 UV386A 0.152-0.168 Water 76.23-84.25 Total 100
TABLE-US-00067 AL76 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVA 93500 PVA 93500 - 0.95-1.05 MKBZ0546V Water 46.78-51.70 AI28 47.27-52.25 (Stock) Total 100
TABLE-US-00068 AL77 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) PVA 93500 PVA 93500 - 0.475-0.525 MKBZ0546V Water 47.25-52.23 AI28 47.27-52.25 (Stock) Total 100
[0256] Rheology Testing
[0257] The rheology testing is discussed above and shown in
[0258]
TABLE-US-00069 Rheology Data Bioink Onset Time Storage Modulus at 50 s AL76 23 19.55 AL77 23 20.62
TABLE-US-00070 AL76 and AL77 Bioinks Print Settings for FS20 DLP 3D System Printer Region Baselayer B Units Layer E Units Power 100 mW/cm.sup.2 Power 100 mW/cm.sup.2 Exposure 1000 ms Exposure 700 ms Time Time Pump 300 ?m Pump 300 ?m Distance Distance Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Uptime 1500 ms Pause Pause Downtime 1000 ms Downtime 1500 ms Downtime 2000 ms Down time 2000 ms Pause Pause
[0259] Compression Testing
[0260] The compression testing is discussed above and shown in
[0261]
[0262]
[0263]
[0264]
[0265]
[0266]
[0267]
TABLE-US-00071 AL76 Bioink Compression Data Area Under Curve % Maximum Strain 3526.93 248.50 1980.15 121.05 2283.67 147.30 2616.64 171.36 2105.07 129.46 2772.87 181.47 2547.56 166.52
TABLE-US-00072 AL77 Bioink Compression Data Area Under Curve % Maximum Strain 2483.12 159.09 2662.50 158.69 3775.61 237.50 3441.43 210.37 3403.70 222.92 2508.97 148.43 3046.06 189.50
[0268] The Polyvinyl Alcohol (PVA) polymer was not incorporated into AI28 Bioink (Stock) when printed at 50 m/W/cm.sup.2. However, the Polyvinyl Alcohol (PVA) polymer was incorporated into AI28 Bioink (Stock) when printed at 100 mW/cm.sup.2.
[0269] Suture Testing
[0270] Using a 45 mm gauge needle, the needle was passed through a solid part of an advanced manufactured hydrogel material (capsulent). The hydrogel material (capsulent) was inspected for any cracking. The purpose of this test was to see if the hydrogel material could be sutured without cracking or falling apart.
[0271]
[0272]
[0273] The AL76 and AL77 Bioinks passed the suture test.
[0274] Interpenetrating Polymer Network Mixtures
[0275] In these examples, one or more of Polyethylene oxide (PEO), Polyvinylpyrrolidone (PVP), and Polyvinyl Alcohol (PVA) polymers were incorporated in synthetic bioinks, as follows.
[0276] Polymers
[0277] Polyethylene Oxide (PEO)
[0278] In these examples, a Polyethylene Oxide (PEO) polymer was incorporated into AW55 Bioink (Stock), as follows.
[0279] Polyethylene Oxide 4000000 (0.5% PEO Stock Solution)
[0280] Polyethylene Oxide 4000000 polymer was added to water, heated at 100? C., and mixed at 600 RPM before incorporating the bioink.
[0281] Polyethylene Oxide 400000 (0.5% PEO Stock Solution)
[0282] Polyethylene Oxide 400000 polymer was added to water, heated at 100? C., and mixed at 600 RPM before incorporating the bioink.
[0283] Polyethylene 100000 (0.5% PEO Stock Solution)
[0284] Polyethylene 100000 polymer was added to water, heated at 100? C., and mixed at 600 RPM.
[0285] Polyvinyl Alcohol (PVA)
[0286] Polyvinyl Alcohol 100000 (4% PVA Stock Solution)
[0287] Polyvinyl alcohol (PVA) was added to water, heated at 200? C., and mixed at 200 RPM before incorporating into the bioink.
[0288] Polyethylene Oxide 100000 (2% PEO Stock Solution)
[0289] Polyethylene Oxide 100000 polymer was added to water, heated at 100? C., and mixed at 600 RPM before incorporating into bioink.
[0290] Polyethylene Oxide 200000 (2% PEO Stock Solution)
[0291] Polyethylene Oxide 200000 polymer was added to water, heated at 100? C., and mixed at 600 RPM before incorporating into bioink.
[0292] Polyethylene Oxide 4000000 (0.4% PEO Stock Solution)
[0293] Polyethylene Oxide 1000000 polymer was added to water, heated at 100? C., and mixed at 600 RPM before incorporating into bioink.
TABLE-US-00073 AW55 Double Bioink (Stock) Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) HPA 19-21 PEGDA PEGDA 6000- 9.5-10.5 6000 BB0308-78 TAC 5.7-6.3 NAP 3.04-3.36 Quinoline 0.641-0.709 Yellow Water 57.12-63.13 Total 100
TABLE-US-00074 AW77 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) AJ55 Stock 50 47.5-52.5 Triacetate PEO 100000 0.095-0.105 PEO 400000 0.095-0.105 PEO 4000000 0.095-0.105 Water 47.22-52.19 Total 100
TABLE-US-00075 AW78 Bioink Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 Triacetate PEO 100000 0.475-0.525 PEO 400000 0.475-0.525 PEO 4000000 0.475-0.525 Water 46.08-50.93 Total 100
TABLE-US-00076 AW79 Bioink (4% PVA Stock Solution) Molecular Registry Stock Reagent Weight (MW) No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 Triacetate 0.95-1.05 PVA 100000 4 11.88-13.13 Water 34.87-38.54 Total 100
TABLE-US-00077 AW80 Bioink (4% PVA Stock Solution) Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 Triacetate 0.95-1.05 PVA 100000 4 23.75-26.25 Water 22.8-25.2 Total 100
TABLE-US-00078 AW81 Bioink (4% PVA Stock Solution) Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 Triacetate PVA 100000 4 47.5-52.5 Water Total 100
TABLE-US-00079 AW82 Bioink Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 PEO 4000000 9.5-10.5 Water 38-42 Total 100
TABLE-US-00080 AW83 Bioink Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 PEO 4000000 4.75-5.25 Water 42.75-47.25 Total 100
TABLE-US-00081 AW84 Bioink (2% PEO Stock Solution) Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 PEO 100000 2 9.5-10.5 Water 38-42 Total 100
TABLE-US-00082 AW85 Bioink (2% PEO Stock Solution) Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 PEO 200000 2 9.5-10.5 Water Total 100
TABLE-US-00083 AW86 Bioink (2% PEO Stock Solution) Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 PEO 200000 2 4.75-5.25 Water 42.75-47.25 Total 100
TABLE-US-00084 AW87 Bioink (0.4% PEO Stock Solution) Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 PEO 4000000 0.4 4.75-5.25 Water 42.75-47.25 Total 100
TABLE-US-00085 AW93 Bioink Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 PVP Mixture 1.43-1.58 Water 46.08-50.93 Total 100
TABLE-US-00086 AW97 Bioink Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 PVP Mixture 1.43-1.58 HEMA 0.048-0.053 Water 46.03-50.87 Total 100
TABLE-US-00087 AW98 Bioink Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) AJ55 Stock 47.5-52.5 Quinoline Yellow PVA 100000 47.5-52.5 Water Total 100
TABLE-US-00088 AW99 Bioink Molecular Stock Reagent Weight (MW) Registry No. Solution (%) Amount (%) HPA 6.65-7.35 PEGDA PEGDA 6000 - 4.75-5.25 6000 BB0308-88 TAC 1.9-2.1 NAP NAP -- NAP -- 1.9-2.1 20210208 20210306 Quinoline 10 0.285-0.315 Yellow PVP 1300000 0.95-1.05 Water 78.57-86.84 Total 100
TABLE-US-00089 AW99 Bioink (with 2/0.3% of PI/Dye) Print Settings for FS20 DLP 3D System Printer Region Baselayer B Units Layer E Units Power 50 mW/cm.sup.2 Power 100 mW/cm.sup.2 Layer 1.4 Time Pump 1 Every Nth Layer Exposure Time 125 ms Exposure 125 ms Time Pump Distance 2000 ?m Pump 2000 ?m Distance Uptime 1000 ms Uptime 2000 ms Uptime Pause 1000 ms Uptime 1000 ms Pause Downtime 1000 ms Downtime 2000 ms Downtime Pause 0 ms Down 6000 ms time Pause Base: Glass/ Titanium Titanium Velcro/Ceramic Model Printed RL48 RL 49 Z compensation Perfused Perfused and and ventilated ventilated for 24 for 24 hours hours Future Direction Print n = 2 Print n = 2
[0294] Swelling Testing
[0295] The swelling of the Bioink hydrogels (dogbones) were observed for 24 hours.
[0296] AW93 Bioink hydrogels (dogbones) swelled about 30% so IPA was decreased from 10% to 7%.
[0297] Compression Testing
[0298] The compression testing is discussed above and shown in
[0299] Compression failure strength and strain are the values of maximum stress (kPa) and maximum strain (%) at which the printed disc fails.
TABLE-US-00090 AW93 Bioink (180 mW/cm.sup.2, 1 s) % Maximum Maximum Dogbone Strain Stress (kPa) Modulus 1 114.37 50.59 58.58 2 144.79 51.47 37.94 3 103.49 51.94 59.42 4 5 6 7 8 Average 120.88 51 51.98 Standard 21.41 0.82 12.17 Deviation
TABLE-US-00091 AW99 Bioink (180 mW/cm.sup.2, 1 s) % Maximum Maximum Dogbone Strain Stress (kPa) Modulus 1 161.32 37.45 22.72 2 173.69 34.87 19.65 3 4 5 6 7 8 Average 167.51 36.16 21.185 Standard 8.75 1.82 2.17 Deviation
[0300]
[0301]
[0302]
[0303]
Method of Making an Advanced Manufactured Interpenetrating Polymer Network (AM-IPN)
[0304] A method for making an advanced manufactured interpenetrating polymer network (AM-IPN) comprises: a) printing one or more of a primary polymer network, a secondary polymer network and one or more crosslinks using a synthetic bioink and a 3D printing technique; b) assembling and/or printing the AM-IPN as described herein to form an assembled AM-IPN.
[0305] In an embodiment, the 3D printing technique is one or more of digital light projection printing (DLP), stereolithography (SLA) printing technique, extrusion 3D printing technique or selective laser sintering 3D printing technique or a combination thereof. In an embodiment, the 3D printing technique is a digital light printing (DLP) printing technique.
Method of Using an Advanced Manufactured Interpenetrating Polymer Network (AM-IPN)
[0306] As method of using an advanced manufactured interpenetrating network (AM-IPN) comprises a) a) modifying a surface of the AM-IPN to attach small airway epithelial cells (SAEC) to form a modified AM-IPN.
[0307] In an embodiment, the method further comprises: b) using the modified AM-IPM for perfusion and ventilation, as described herein.
[0308] The embodiments and examples set forth herein are presented to best explain the present invention and its practical application and to thereby enable those skilled in the art to make and utilize the invention. However, those skilled in the art will recognize that the foregoing description and examples have been presented for the purpose of illustration and example only. The description as set forth is not intended to be exhaustive or to limit the invention to the precise form disclosed. Many modifications and variations are possible in light of the above teaching without departing from the spirit and scope of the following claims. The invention is specifically intended to be as broad as the claims below and their equivalents.
[0309] Any references to implementations or elements or acts of the systems and methods herein referred to in the singular can include implementations including a plurality of these elements, and any references in plural to any implementation or element or act herein can include implementations including only a single element. References in the singular or plural form are not intended to limit the presently disclosed systems or methods, their components, acts, or elements to single or plural configurations. References to any act or element being based on any information, act or element may include implementations where the act or element is based at least in part on any information, act, or element.
[0310] As utilized herein, the terms approximately, about, substantially, and similar terms are intended to have a broad meaning in harmony with the common and accepted usage by those of ordinary skill in the art to which the subject matter of this disclosure pertains. It should be understood by those of skill in the art who review this disclosure that these terms are intended to allow a description of certain features described and claimed without restricting the scope of these features to the precise numerical ranges provided. Accordingly, these terms should be interpreted as indicating that insubstantial or inconsequential modifications or alterations of the subject matter described and claimed are considered to be within the scope of the disclosure as recited in the appended claims.
[0311] It should be noted that the term exemplary and variations thereof, as used herein to describe various embodiments, are intended to indicate that such embodiments are possible examples, representations, or illustrations of possible embodiments (and such terms are not intended to connote that such embodiments are necessarily extraordinary or superlative examples).
[0312] The term coupled and variations thereof, as used herein, means the joining of two members directly or indirectly to one another. Such joining may be stationary (e.g., permanent or fixed) or moveable (e.g., removable or releasable). Such joining may be achieved with the two members coupled directly to each other, with the two members coupled to each other using a separate intervening member and any additional intermediate members coupled with one another, or with the two members coupled to each other using an intervening member that is integrally formed as a single unitary body with one of the two members. If coupled or variations thereof are modified by an additional term (e.g., directly coupled), the generic definition of coupled provided above is modified by the plain language meaning of the additional term (e.g., directly coupled means the joining of two members without any separate intervening member), resulting in a narrower definition than the generic definition of coupled provided above. Such coupling may be mechanical, electrical, or fluidic.
[0313] Any implementation disclosed herein may be combined with any other implementation, and references to an implementation, some implementations, an alternate implementation, various implementations, one implementation or the like are not necessarily mutually exclusive and are intended to indicate that a particular feature, structure, or characteristic described in connection with the implementation may be included in at least one implementation. Such terms as used herein are not necessarily all referring to the same implementation. Any implementation may be combined with any other implementation, inclusively or exclusively, in any manner consistent with the aspects and implementations disclosed herein.
[0314] References to or may be construed as inclusive so that any terms described using or may indicate any of a single, more than one, and all of the described terms. References to at least one of a conjunctive list of terms may be construed as an inclusive OR to indicate any of a single, more than one, and all of the described terms. For example, a reference to at least one of A and B can include only A, only B, as well as both A and B. Elements other than A and B can also be included.
[0315] References herein to the positions of elements (e.g., top, bottom, above, below) are merely used to describe the orientation of various elements in the FIGURES. It should be noted that the orientation of various elements may differ according to other exemplary embodiments, and that such variations are intended to be encompassed by the present disclosure.
[0316] Although the figures and description may illustrate a specific order of method steps, the order of such steps may differ from what is depicted and described, unless specified differently above. Also, two or more steps may be performed concurrently or with partial concurrence, unless specified differently above. Such variation may depend, for example, on the software and hardware systems chosen and on designer choice. All such variations are within the scope of the disclosure. Likewise, software implementations of the described methods could be accomplished with standard programming techniques with rule-based logic and other logic to accomplish the various connection steps, processing steps, comparison steps, and decision steps.
[0317] Where technical features in the drawings, detailed description or any claim are followed by reference signs, the reference signs have been included to increase the intelligibility of the drawings, detailed description, and claims. Accordingly, neither the reference signs nor their absence have any limiting effect on the scope of any claim elements.
[0318] The systems and methods described herein may be embodied in other specific forms without departing from the characteristics thereof. The foregoing implementations are illustrative rather than limiting of the described systems and methods. Scope of the systems and methods described herein is thus indicated by the appended claims, rather than the foregoing description, and changes that come within the meaning and range of equivalency of the claims are embraced therein.